Cargando…
Prepared omadacycline for injection: Nine-day stability and sterility in an elastomeric pump
OBJECTIVE: To investigate compatibility, stability, and microbiologic risk of omadacycline 1 mg/mL when prepared in an elastomeric infusion pump and stored under refrigeration for 9 days based upon requests for information from healthcare providers. METHODS: Omadacycline was reconstituted to 1 mg/mL...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643752/ https://www.ncbi.nlm.nih.gov/pubmed/36385797 http://dx.doi.org/10.1177/20503121221135568 |
_version_ | 1784826586805043200 |
---|---|
author | Bower, Jason Wright, Kelly Burdette, Jason |
author_facet | Bower, Jason Wright, Kelly Burdette, Jason |
author_sort | Bower, Jason |
collection | PubMed |
description | OBJECTIVE: To investigate compatibility, stability, and microbiologic risk of omadacycline 1 mg/mL when prepared in an elastomeric infusion pump and stored under refrigeration for 9 days based upon requests for information from healthcare providers. METHODS: Omadacycline was reconstituted to 1 mg/mL with sodium chloride 0.9% w/v or dextrose 5% w/v in SMARTeZ(®) elastomeric infusion pumps and refrigerated for up to 9 days. Samples were taken daily and tested for appearance, pH, osmolality, chemical composition, and particulate matter. For a microbial challenge study, the pumps were spiked with a challenge microorganism (Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Candida albicans, or Aspergillus brasiliensis) and samples were plated daily for 9 days to assess microbial survival. RESULTS: Appearance, pH, osmolality, percent label claim, and particulate matter results remained essentially unchanged for omadacycline solutions in either diluent over the 9-day study. No > 0.5-log day-to-day increases in the challenge-microorganism populations were measured in diluted omadacycline pumps or positive controls. With omadacycline, no growth was seen for S. aureus or E. coli in either diluent, nor for P. aeruginosa in dextrose 5% w/v. Reduction of C. albicans and A. brasiliensis populations over time was similar between omadacycline solutions and positive controls. CONCLUSION: After reconstitution, omadacycline for injection was stable and remained within specifications for use for up to 9 days when refrigerated. |
format | Online Article Text |
id | pubmed-9643752 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-96437522022-11-15 Prepared omadacycline for injection: Nine-day stability and sterility in an elastomeric pump Bower, Jason Wright, Kelly Burdette, Jason SAGE Open Med Original Research Article OBJECTIVE: To investigate compatibility, stability, and microbiologic risk of omadacycline 1 mg/mL when prepared in an elastomeric infusion pump and stored under refrigeration for 9 days based upon requests for information from healthcare providers. METHODS: Omadacycline was reconstituted to 1 mg/mL with sodium chloride 0.9% w/v or dextrose 5% w/v in SMARTeZ(®) elastomeric infusion pumps and refrigerated for up to 9 days. Samples were taken daily and tested for appearance, pH, osmolality, chemical composition, and particulate matter. For a microbial challenge study, the pumps were spiked with a challenge microorganism (Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Candida albicans, or Aspergillus brasiliensis) and samples were plated daily for 9 days to assess microbial survival. RESULTS: Appearance, pH, osmolality, percent label claim, and particulate matter results remained essentially unchanged for omadacycline solutions in either diluent over the 9-day study. No > 0.5-log day-to-day increases in the challenge-microorganism populations were measured in diluted omadacycline pumps or positive controls. With omadacycline, no growth was seen for S. aureus or E. coli in either diluent, nor for P. aeruginosa in dextrose 5% w/v. Reduction of C. albicans and A. brasiliensis populations over time was similar between omadacycline solutions and positive controls. CONCLUSION: After reconstitution, omadacycline for injection was stable and remained within specifications for use for up to 9 days when refrigerated. SAGE Publications 2022-11-06 /pmc/articles/PMC9643752/ /pubmed/36385797 http://dx.doi.org/10.1177/20503121221135568 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Article Bower, Jason Wright, Kelly Burdette, Jason Prepared omadacycline for injection: Nine-day stability and sterility in an elastomeric pump |
title | Prepared omadacycline for injection: Nine-day stability and sterility
in an elastomeric pump |
title_full | Prepared omadacycline for injection: Nine-day stability and sterility
in an elastomeric pump |
title_fullStr | Prepared omadacycline for injection: Nine-day stability and sterility
in an elastomeric pump |
title_full_unstemmed | Prepared omadacycline for injection: Nine-day stability and sterility
in an elastomeric pump |
title_short | Prepared omadacycline for injection: Nine-day stability and sterility
in an elastomeric pump |
title_sort | prepared omadacycline for injection: nine-day stability and sterility
in an elastomeric pump |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643752/ https://www.ncbi.nlm.nih.gov/pubmed/36385797 http://dx.doi.org/10.1177/20503121221135568 |
work_keys_str_mv | AT bowerjason preparedomadacyclineforinjectionninedaystabilityandsterilityinanelastomericpump AT wrightkelly preparedomadacyclineforinjectionninedaystabilityandsterilityinanelastomericpump AT burdettejason preparedomadacyclineforinjectionninedaystabilityandsterilityinanelastomericpump |